ALNY
Alnylam Pharmaceuticals Inc
246.50$
-2.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | -108.0% | – | |
| – | +59.7% | -20.6% | -11.7% | -51.9% | +744.9% | +36.9% | +20.5% | -4.6% | +13.4% | -41.6% | -1.8% | |
| – | +38.5% | +65.0% | +22.9% | +70.0% | +10.8% | -20.0% | +18.5% | +39.2% | -3.9% | +22.7% | +28.0% | |
| – | – | +54.4% | +35.2% | +90.8% | +8.4% | -22.4% | +42.6% | +37.7% | – | – | – | |
| – | – | -51.0% | -116.9% | – | +792.2% | -103.2% | – | – | – | -2,089.8% | – | |
| – | +44.5% | +398.5% | +61.4% | +21.8% | +10.5% | -49.8% | +8.5% | -5.6% | -13.7% | -44.9% | +71.2% | |
| – | -41.5% | – | -303.6% | – | -253.0% | +4.3% | -37.2% | – | -298.6% | -65.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -97.6% | +57.7% | -56.9% | +1,249.8% | – | -64.8% | -17.9% | +5.3% | – | – | – | |
| – | +0.0% | +0.0% | -180.0% | -75.0% | +0.0% | – | +150.0% | -49.2% | -100.0% | – | – | |
| – | -16.3% | -71.1% | +532.6% | -94.2% | +1,157.3% | +20.9% | +25.3% | -65.9% | -59.6% | +70.9% | -203.8% | |
| – | +380.3% | -88.0% | +3,450.9% | -149.6% | – | -139.8% | – | -85.6% | -215.7% | – | +348.8% | |
| – | – | – | – | – | – | – | – | – | – | -201.5% | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.